If MAPS gains FDA approval in the U.S. the organization will have a monopoly on the market, and will aim to build the momentum and political leverage necessary to export MDMA-assisted therapy worldwide. But experts warn that the long-term mission to bring the therapy to war-afflicted regions is fraught.
↧